PaizaBio, Inc., a contract manufacturing organization based in New Mexico, has secured an agreement with Taiwan-based JHL Biotech, Inc. to provide fill-finish services for multiple JHL projects. PaizaBio will provide these services to JHL through its Hangzhou, China-based strategic partner, Ausia BioTech.

Per terms of the agreement, PaizaBio will aseptically fill-and-finish compounds into injectable formulations for clinical trial applications. The compounds are molecular entities targeting both oncology and immunological therapies.

JHL Biotech will supply PaizaBio with active biological ingredients produced at its manufacturing facility in Wuhan, China. PaizaBio will provide contract fill-and-finish services and will cold-ship the material to JHL Biotech for use in clinical trials.

Source: PaizaBio